Lypqozet Dosage

Recommended Dosing

The dosage range of LYPQOZET is 10/10 mg/day to 10/80 mg/day. The recommended starting dose of LYPQOZET is 10/10 mg/day or 10/20 mg/day. LYPQOZET can be administered as a single dose at any time of the day, with or without food. The recommended starting dose for patients who require a larger reduction in LDL-C (greater than 55%) is 10/40 mg/day. After initiation and/or upon titration of LYPQOZET, lipid levels should be analyzed within 2 or more weeks and dosage adjusted accordingly.

Patients should swallow LYPQOZET tablets whole. Tablets should not be crushed, dissolved, or chewed.

Patients with Homozygous Familial Hypercholesterolemia

The dosage of LYPQOZET in patients with homozygous familial hypercholesterolemia is 10/40 mg/day or 10/80 mg/day. LYPQOZET should be used as an adjunct to other lipid-lowering treatments (e. g., LDL apheresis) in these patients or if such treatments are unavailable.

Coadministration with Other Drugs

Bile Acid Sequestrants

Dosing of LYPQOZET should occur either greater than or equal to 2 hours before or greater than or equal to 4 hours after administration of a bile acid sequestrant [see Drug Interactions (7.12)].

Cyclosporine, Clarithromycin, Itraconazole, or Certain HIV/HCV Antiviral Agents

In patients taking cyclosporine or the HIV protease inhibitors (tipranavir plus ritonavir) or the hepatitis C protease inhibitor (telaprevir), therapy with LYPQOZET should be avoided. In patients with HIV taking lopinavir plus ritonavir, caution should be used when prescribing LYPQOZET and the lowest dose necessary employed. In patients taking clarithromycin, itraconazole, or in patients with HIV taking a combination of saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, therapy with LYPQOZET should be limited to 10/20 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of LYPQOZET is employed. In patients taking hepatitis C antiviral agents containing elbasvir and grazoprevir, therapy with LYPQOZET should not exceed 10/20 mg. In patients taking the HIV protease inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, therapy with LYPQOZET should be limited to 10/40 mg, and appropriate clinical assessment is recommended to ensure that the lowest dose necessary of LYPQOZET is employed [see Warnings and Precautions (5.1) and Drug Interactions (7)].

Other Concomitant Lipid-Lowering Therapy

The combination of LYPQOZET and gemfibrozil is not recommended [see Warnings and Precautions (5.1) and Drug Interactions (7.4)].